GO:0032021 NELF complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032021 (NELF complex) is a five-subunit negative elongation factor that binds RNA polymerase II and induces promoter-proximal transcriptional pausing.
• The human NELF complex comprises NELF-A (WHSC2), NELF-B (COBRA1), NELF-C (TH1L), NELF-D (TH1L-like), and NELF-E (RDBP).
• NELF acts together with DSIF (SUPT4H1/SUPT5H) to stabilize paused Pol II and is released by P-TEFb-mediated phosphorylation.
• Integrator complex regulates NELF-mediated pause/release and processivity at coding genes.
• NELF-E (RDBP) is implicated in breast cancer through an epigenetic axis with SLUG and KAT2B.
• Dysregulation of NELF components affects promoter-proximal pausing, gene expression, and cellular stress responses.
Description
The NELF complex (negative elongation factor) is a conserved cellular component that associates with RNA polymerase II (Pol II) to induce transcriptional pausing near promoters. This pausing is a critical regulatory checkpoint in metazoan gene expression, enabling rapid and synchronous activation of developmental and stimulus-responsive genes. The complex was initially identified as a factor that inhibits elongation by Pol II in vitro, and subsequent structural and genomic studies have defined its subunit composition and mechanism. NELF is composed of five proteins in humans: NELF-A, NELF-B, NELF-C, NELF-D, and NELF-E. Together with the DSIF complex (SUPT4H1 and SUPT5H), NELF stabilizes Pol II in a paused state approximately 20-60 bp downstream of the transcription start site. This paused state is a key regulatory intermediate that controls the transition from initiation to productive elongation. Researchers study NELF to understand how gene expression is dynamically regulated during development, differentiation, and disease. The complex is also a target of the Integrator complex, which regulates pause release and processivity at coding genes. Recent structural studies have revealed distinct conformations of NELF that modulate its interaction with Pol II and its role in pausing. Defects in NELF components have been linked to cancer and other pathologies, making it a subject of intense investigation.
NELF complex At A Glance
| GO ID | GO:0032021 |
|---|---|
| GO term | NELF complex |
| Ontology | cellular_component |
| Synonym | negative elongation factor complex |
| Major function | Induces transcriptional pausing by associating with RNA polymerase II |
| Subunit composition | Five proteins: NELF-A, NELF-B, NELF-C, NELF-D, NELF-E |
| Associated factors | DSIF (SUPT4H1/SUPT5H), P-TEFb, Integrator complex |
| Regulatory role | Controls promoter-proximal pausing and pause release |
What Is GO:0032021?
The NELF complex is a cellular component defined by Gene Ontology as a complex of five proteins (NELF-A, -B, -C, -D, and -E in human) that can physically associate with RNA polymerase II to induce transcriptional pausing. It is also known as the negative elongation factor complex. This complex acts as a negative regulator of transcription elongation, promoting a paused state that is essential for proper gene regulation.
Why Is NELF complex Important in Cell Biology?
The NELF complex is essential for the regulation of RNA polymerase II pausing, a rate-limiting step in gene expression that affects diverse biological processes including development, cell cycle, and stress responses. Its dysfunction has been implicated in cancer, where NELF-E (RDBP) promotes breast cancer carcinogenesis through an epigenetic axis with SLUG and KAT2B. Additionally, NELF is involved in the removal of defective Pol II complexes at a promoter-proximal pause checkpoint, highlighting its role in quality control of transcription. Understanding NELF function provides insights into transcriptional regulation and offers potential therapeutic targets for diseases characterized by aberrant gene expression.
• Regulates promoter-proximal pausing of RNA polymerase II, a key checkpoint in gene expression.
• Essential for proper developmental gene activation and stimulus-responsive transcription.
• Implicated in breast cancer carcinogenesis via NELF-E-SLUG-KAT2B epigenetic axis.
• Interacts with Integrator complex to regulate pause/release and processivity at coding genes.
• Participates in quality control by removing defective Pol II complexes at pause checkpoints.
• Structural studies reveal distinct conformations that modulate pausing.
• Target for therapeutic intervention in cancers with dysregulated pause control.
• Provides a model for studying the interplay between transcription elongation and RNA processing.
• NELF-B/C/E ternary complex structure offers insights into assembly and function.
• Dysregulation leads to widespread changes in gene expression programs.
What Happens During NELF complex?
Promoter-proximal pausing
In simple terms: NELF helps put the brakes on transcription shortly after it starts.
After transcription initiation, RNA polymerase II (Pol II) synthesizes a short RNA transcript and then pauses approximately 20-60 nucleotides downstream of the transcription start site. The NELF complex, together with DSIF, binds to Pol II and stabilizes this paused state, preventing premature elongation. This pausing is a critical regulatory step that allows for synchronous gene activation and integration of cellular signals.
Pause release and elongation
In simple terms: The brakes are released when specific enzymes modify NELF and DSIF.
Pause release is triggered by the positive transcription elongation factor b (P-TEFb), which phosphorylates the DSIF subunit SPT5 and the Pol II C-terminal domain, and also phosphorylates NELF-E, leading to NELF dissociation. This allows Pol II to transition into productive elongation. The Integrator complex also regulates NELF-mediated pause/release and processivity at coding genes.
Quality control at the pause checkpoint
In simple terms: NELF helps identify and remove broken transcription machines.
Recent studies have shown that NELF participates in a promoter-proximal pause checkpoint that monitors the integrity of Pol II complexes. Defective Pol II complexes are removed through redundant pathways involving NELF, ensuring transcriptional fidelity.
Structural dynamics of NELF
In simple terms: NELF changes shape to perform its different jobs.
Cryo-electron microscopy structures of the Pol II-DSIF-NELF complex have revealed that NELF adopts distinct conformations that modulate its interaction with Pol II and its role in pausing. The NELF-B/C/E ternary complex structure provides insights into subunit assembly and function. These structural insights are essential for understanding how NELF regulates transcription.
Key Genes Involved in GO:0032021 NELF complex
The NELF complex is composed of five core subunits, each encoded by a distinct gene, and its function is modulated by interacting proteins and kinases.
| Gene | Major Role | Research Relevance |
|---|---|---|
| WHSC2 (NELF-A) | Subunit A of NELF complex; involved in pausing | Wolf-Hirschhorn syndrome candidate; structural studies |
| COBRA1 (NELF-B) | Subunit B; essential for NELF assembly and pausing | Breast cancer susceptibility; interacts with BRCA1 |
| TH1L (NELF-C/D) | Subunit C/D; RNA-binding and pausing | Regulates pause release; target of P-TEFb |
| RDBP (NELF-E) | Subunit E; RNA recognition motif; binds RNA | Implicated in breast cancer via SLUG-KAT2B axis |
| SUPT4H1 (SPT4) | DSIF subunit; cooperates with NELF | Pausing and elongation regulation |
| SUPT5H (SPT5) | DSIF subunit; phosphorylated by P-TEFb | Pause release; processivity |
| CDK9 | Kinase subunit of P-TEFb; phosphorylates NELF/DSIF | Pause release; therapeutic target |
| CCNT1 (Cyclin T1) | Regulatory subunit of P-TEFb | Pause release; transcription regulation |
| INTS11 | Integrator subunit; regulates NELF-mediated pausing | Pause/release at coding genes |
| INTS9 | Integrator subunit; interacts with NELF | Transcription termination |
| BRCA1 | Interacts with NELF-B; DNA repair | Breast cancer; transcription-coupled repair |
| SLUG (SNAI2) | Transcription factor; cooperates with NELF-E | Breast cancer metastasis |
| KAT2B (PCAF) | Histone acetyltransferase; epigenetic axis with NELF-E | Breast cancer carcinogenesis |
| POLR2A | Largest subunit of RNA polymerase II | Target of NELF-mediated pausing |
| CDK12 | Kinase; regulates elongation and pause release | Transcription regulation; cancer |
| HEXIM1 | Inhibits P-TEFb; modulates pause release | Transcription regulation |
| BRD4 | Bromodomain protein; recruits P-TEFb | Pause release; cancer therapy |
How Is NELF complex Regulated?
The NELF complex is regulated by phosphorylation. P-TEFb (CDK9/Cyclin T1) phosphorylates NELF-E and the DSIF subunit SPT5, leading to NELF dissociation and pause release. Integrator complex also regulates NELF-mediated pausing at coding genes. Additionally, NELF stability and assembly may be influenced by its subunit interactions and post-translational modifications. The balance between NELF and P-TEFb activity determines the duration of pausing and the efficiency of elongation.
NELF complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RDBP (NELF-E) | Breast cancer carcinogenesis | Knockout or knockdown in breast cancer cell lines (e.g., MCF-7) |
| COBRA1 (NELF-B) | Breast cancer susceptibility | Conditional knockout mouse models |
| WHSC2 (NELF-A) | Wolf-Hirschhorn syndrome | Patient-derived iPSCs with haploinsufficiency |
| SUPT5H | Developmental disorders | CRISPR knock-in of patient mutations |
| CDK9 | Cancer, inflammation | Small molecule inhibitors in xenograft models |
NELF in breast cancer
NELF-E (RDBP) has been shown to promote breast cancer carcinogenesis through an epigenetic axis involving SLUG and KAT2B. Knockdown of NELF-E reduces tumor growth and metastasis in breast cancer models, suggesting that NELF-E is a potential therapeutic target. The interaction between NELF-E and SLUG modulates the expression of genes involved in epithelial-mesenchymal transition.
NELF and transcriptional dysregulation in cancer
Dysregulation of promoter-proximal pausing is a common feature of cancer cells. NELF components are frequently overexpressed in various cancers, leading to altered expression of oncogenes and tumor suppressors. Targeting the NELF complex or its regulators (e.g., P-TEFb) is being explored as a therapeutic strategy.
NELF in developmental disorders
NELF-A is encoded by WHSC2, a gene located in the Wolf-Hirschhorn syndrome critical region. Although direct mutations in WHSC2 are not a primary cause of the syndrome, haploinsufficiency may contribute to developmental defects. Further research is needed to establish a definitive link.
From NELF complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NELF-E loss affect breast cancer growth? | Knockout of RDBP in breast cancer cell lines and mouse xenografts |
| How does NELF-A mutation affect pausing? | Point mutation knock-in of WHSC2 in HEK293T cells |
| What is the role of NELF-B in DNA repair? | Knock-in of tagged COBRA1 for interaction studies |
| Can NELF-C/D phosphorylation be monitored? | Knock-in of phospho-tagged TH1L |
| Does NELF overexpression alter global transcription? | Overexpression of all NELF subunits in HeLa cells |
| How does NELF cooperate with Integrator? | Knockout of INTS11 in combination with NELF knockdown |
How to Study the NELF complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genome-wide binding of Pol II and NELF | Mapping paused Pol II |
| PRO-seq | Nascent RNA and polymerase position | Measuring pause release |
| Cryo-EM | 3D structure of complexes | Understanding NELF-Pol II interactions |
| AP-MS | Protein-protein interactions | Identifying NELF partners |
| RNA-seq | Gene expression changes | Knockout/knockdown effects |
| In vitro transcription | Pausing efficiency | Reconstitution with purified factors |
| FRAP | Protein dynamics | NELF turnover at promoters |
| Luciferase reporter | Pause release activity | Screening for regulators |
Genomic methods to study NELF function
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) for Pol II and NELF subunits can map paused Pol II genome-wide. Precision nuclear run-on sequencing (PRO-seq) and global run-on sequencing (GRO-seq) measure nascent transcription and pause release. These methods are essential for understanding how NELF regulates gene expression.
Proteomic and structural approaches
Affinity purification coupled with mass spectrometry (AP-MS) can identify NELF-interacting proteins. Cryo-electron microscopy (cryo-EM) has been used to solve structures of Pol II-DSIF-NELF complexes, revealing conformational changes. These structural studies provide mechanistic insights into pausing.
Functional assays for pausing
In vitro transcription assays with purified Pol II, DSIF, and NELF can reconstitute pausing. RNA interference or CRISPR knockout of NELF subunits followed by RNA-seq can reveal changes in gene expression. Luciferase reporter assays with paused promoters can measure pause release efficiency.
Imaging and live-cell studies
Fluorescence recovery after photobleaching (FRAP) and single-molecule imaging can track NELF dynamics at transcription sites. Live-cell imaging of tagged NELF subunits can reveal real-time assembly and disassembly.
How CRISPR Can Be Used to Study GO:0032021 NELF complex
Knockout
CRISPR knockout of NELF subunits (e.g., RDBP, COBRA1) in cell lines can abolish pausing and lead to widespread changes in gene expression. Knockout models are useful for studying the loss-of-function effects on transcription and cell viability.
Point Mutation
Introducing point mutations in NELF subunits (e.g., in the RNA recognition motif of NELF-E) can dissect specific functions such as RNA binding versus protein-protein interactions. These models help identify critical residues for pausing.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins into endogenous NELF genes allows for precise localization and interaction studies. Tagged knock-in models are valuable for ChIP-seq and imaging.
Overexpression
Overexpression of NELF subunits can enhance pausing and alter differentiation or proliferation. This approach is useful for gain-of-function studies and for testing therapeutic interventions.
How EDITGENE Supports NELF complex Research
Researchers studying NELF complex-related genes often need to determine whether a candidate gene is causally involved in transcriptional regulation, cancer, or developmental disorders. EDITGENE provides comprehensive CRISPR-based services to create precise cellular models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for NELF complex research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NELFE Knockout HEK293 Cell Line | EDJ-KQ50731 | Human | 7936 | Details Get a Quote |
| NELFE Knockout HeLa Cell Line | EDJ-KQ54807 | Human | 7936 | Details Get a Quote |
| NELFE Knockout A-549 Cell Line | EDJ-KQ63297 | Human | 7936 | Details Get a Quote |
| NELFE Knockout HCT 116 Cell Line | EDJ-KQ71766 | Human | 7936 | Details Get a Quote |
Frequently Asked Questions About NELF complex
What is the NELF complex?
The NELF complex (negative elongation factor) is a five-subunit protein complex that associates with RNA polymerase II to induce transcriptional pausing.
What genes are involved in the NELF complex?
The human NELF complex comprises NELF-A (WHSC2), NELF-B (COBRA1), NELF-C (TH1L), NELF-D (TH1L-like), and NELF-E (RDBP).
What is the function of GO:0032021?
GO:0032021 is the Gene Ontology term for the NELF complex, which functions to induce promoter-proximal pausing of RNA polymerase II.
How does NELF regulate transcription?
NELF binds to Pol II and stabilizes the paused state, preventing elongation until phosphorylated by P-TEFb.
What diseases are associated with NELF complex?
NELF-E (RDBP) is implicated in breast cancer through an epigenetic axis with SLUG and KAT2B.
What is the difference between NELF and DSIF?
DSIF (SUPT4H1/SUPT5H) cooperates with NELF to establish pausing; both are released by P-TEFb phosphorylation.
How can I study NELF complex in the lab?
Common methods include ChIP-seq, PRO-seq, CRISPR knockout, and cryo-EM.
What are the subunits of NELF complex?
NELF-A, NELF-B, NELF-C, NELF-D, and NELF-E.
Is NELF complex conserved in yeast?
No, NELF is metazoan-specific; yeast lack a clear NELF homolog.
What is the role of NELF in cancer?
NELF-E promotes breast cancer carcinogenesis and is a potential therapeutic target.
Conclusion
The NELF complex (GO:0032021) is a central regulator of RNA polymerase II pausing, with critical roles in gene expression, development, and disease. Its five subunits assemble into a dynamic machine that responds to cellular signals through phosphorylation and interactions with DSIF, P-TEFb, and Integrator. Dysregulation of NELF has been linked to breast cancer and other pathologies, making it an attractive target for therapeutic intervention. Continued research using advanced CRISPR models and genomic methods will further elucidate its mechanisms and potential as a drug target.
References
- 1. Schier AC et al.. 2020. Structure and mechanism of the RNA polymerase II transcription machinery.. Genes Dev 34(7-8):465-488 PMID: 32238450
- 2. Zhang J et al.. 2023. Dependency of NELF-E-SLUG-KAT2B epigenetic axis in breast cancer carcinogenesis.. Nat Commun 14(1):2439 PMID: 37117180
- 3. Cao Y et al.. 2023. Structural basis of the human negative elongation factor NELF-B/C/E ternary complex.. Biochem Biophys Res Commun 677:155-161 PMID: 37591184
- 4. Fianu I et al.. 2024. Structural basis of Integrator-dependent RNA polymerase II termination.. Nature 629(8010):219-227 PMID: 38570683
- 5. Vos SM et al.. 2018. Structure of paused transcription complex Pol II-DSIF-NELF.. Nature 560(7720):601-606 PMID: 30135580
- 6. Stadelmayer B et al.. 2014. Integrator complex regulates NELF-mediated RNA polymerase II pause/release and processivity at coding genes.. Nat Commun 5:5531 PMID: 25410209
- 7. Su BG et al.. 2024. Distinct negative elongation factor conformations regulate RNA polymerase II promoter-proximal pausing.. Mol Cell 84(7):1243-1256.e5 PMID: 38401543
- 8. Blears D et al.. 2024. Redundant pathways for removal of defective RNA polymerase II complexes at a promoter-proximal pause checkpoint.. Mol Cell 84(24):4790-4807.e11 PMID: 39504960
